Hyperimmune serum containing Histophilus somni rHsp60, rOMP40 and Actinobacillus pleuropneumoniae LPS antibodies as supplementary treatment for calf respiratory diseases
Year: 2025
Type: article
Abstract: Bovine respiratory disease (BRD) in dairy heifer calves cause significant economic losses associated with treatment costs, reduced growth rate and mortality. Bovine hyperimmune serum was produced in cows hyperimmunized with three conservative antigens (Histophilus somni rHsp60, H. somni rOMP40, and Actinobacillus pleuropneumoniae LPS core oligosaccharide), which exhibit broad cross-reactivity with several Gram-negative bacteria. Dairy heifer calves received serum subcutaneously on the first day of treatment for BRD, as an additive to antibiotics and anti-inflammatory drugs. Health status was estimated on a modified point scale system on days 1, 7 and 14th of the treatment. The calves were divided into four groups (10 per group): two with moderate signs of BRD with or without (control) hyperimmune serum application and two with severe signs of BRD. At day 1,7,14 of treatment and day 180 of life, plasma fibrinogen, serum haptoglobin, serum amyloid A, IgG1, IgG2, and IgM. Harvested hyperimmune serum contained high levels of IgG1 and IgG2 antibodies against homologous antigens. The supplementary application of hyperimmune serum concurrently to antibiotic and NSAIDs treatment of respiratory tract infections in dairy heifer calves shortened the appearance and reduced the intensity of clinical signs compared with calves treated without the use of serum.
Source: Scientific Reports
Language: English
Topic: Animal health and immunology
Subfield: Small Animals
Field: Veterinary
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,690
Award: G6279288430
OpenAlex ID: W4410884196